Evidence map›Paper›PMID 26877758›Full record

ArticleFuture virology

Recent advances in management of the HIV/HCV coinfected patient.

Cindy J Bednasz, Joshua R Sawyer, Anthony Martinez, Patrick G Rose, Samantha S Sithole, Holly R Hamilton, Farzia S Kaufman, Charles S Venuto, Qing Ma, Andrew Talal and 1 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future virology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03025074 (Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03025074 recruitingnot on this map

Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases

Typeobservational_patient_registrySponsorState University of New York at BuffaloRan2013 to 2099Enrolled1,000ConditionsNon-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Cindy J BednaszSchool of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
Joshua R SawyerSchool of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA.
Anthony MartinezBuffalo General Medical Center, University at Buffalo, Room. 617F, B Building, Buffalo, New York 14203, USA; Hepatology, Division of Gastroenterology, Hepatology & Nutrition, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA.
Patrick G RoseSchool of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA.
Samantha S SitholeTranslational Pharmacology Research Core, niversity at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
Holly R HamiltonNew York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA; Immunodeficiency Services Clinic, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA.
Farzia S KaufmanTranslational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203-1101, USA.
Charles S VenutoCenter for Human Experimental Therapeutics, University of Rochester Medical Center, 265 Crittenden Blvd. CU 420694, Rochester, New York 14642-0694, USA.
Qing MaSchool of Pharmacy & Pharmaceutical Sciences, New York State Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
Andrew TalalUBMD Center for Clinical Care & Research in Liver Disease, 875 Ellicott Street, Suite 6090, Buffalo, New York 14203, USA; Division of Gastroenterology, Hepatology and Nutrition, Clinical & Translational Research Center, 875 Ellicott Street, Suite 6090, Buffalo, New York 14203, USA.
Gene D MorsePharmacy Practice (Medicine and Pediatrics), School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
University at Buffalo, State University of New York · USBuffalo General Medical Center · USCenter for Clinical Research (United States) · USUniversity of Rochester Medical Center · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
University of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7M
Quantitative Pharmacology for Accelerating Drug Development for HIV/HCV Co-Infected PatientsK23AI108355 · NIAID · UNIVERSITY OF ROCHESTER · PI VENUTO, CHARLES STANLEY · 2015 to 2019
$720k
NIAID NIH HHS K23 AI108355NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

Chronic hepatitis C virus (HCV) is a global epidemic, affecting approximately 150 million individuals throughout the world. The implications of HCV infection have been magnified in those who are infected with both HCV and the HIV as liver disease progression, liver failure and liver-related death are increased, particularly in those without well-controlled HIV disease. The development of direct-acting antiviral agents for HCV that allow shorter treatment periods with increased efficacy and decreased adverse events have greatly changed the outlook for HCV-infected individuals. With these advancements, growing treatment options for the coinfected population have also come. This review will address pharmacotherapy issues in the HIV/HCV coinfected population.

Indexed as

direct-acting antiviralHCVHIVnull responderrelapsesustained virologic response

Identifiers

PMID26877758
PMCPMC4751983
OpenAlexW2194118227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.